CTOs on the Move

Amolyt Pharma

www.amolytpharma.com

 
Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

RxHub

RxHub LLC is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

US Micron

US Micron is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Francks Pharmacies

Francks Pharmacies is a Ocala, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novadoz

Novadoz Pharmaceuticals is a sales and marketing subsidiary for MSN Labs portfolio of finished dosage forms. MSN Labs is a global leader in the development and manufacturing of APIs (active pharmaceutical ingredients).

Mustang Bio

Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.